Skip to main content

Table 5 Clinical characteristics, hormonal levels, metabolic profile and PAF-AH activity of the apoC1–317H1/H2 genotypes in PCOS patients and controls

From: Effects of apoC1 genotypes on the hormonal levels, metabolic profile and PAF-AH activity in Chinese women with polycystic ovary syndrome

 

Controls

PCOS

H1H1 (n = 318)

H1H2 + H2H2 (n = 163 + 25)

H1H1 (n = 370)

H1H2 + H2H2 (n = 177 + 28)

Age (yr)

28.17 ± 4.17

27.56 ± 4.21

24.68 ± 4.03a, b

24.63 ± 3.84a, b

BMI (kg/m2)

21.18 ± 2.95

20.91 ± 2.81

22.94 ± 4.23a, b

23.41 ± 4.29a, b

Waist circumference (cm)

73.36 ± 7.96

73.35 ± 8.61

79.35 ± 11.36a, b

80.06 ± 12.02a, b

Waist-to-hip ratio

0.81 ± 0.06

0.82 ± 0.06

0.85 ± 0.07a, b

0.85 ± 0.08a, b

F-G score

0.25 ± 0.76

0.19 ± 0.68

1.77 ± 2.06a, b

1.63 ± 2.10a, b

Acne grade score

0.11 ± 0.31

0.07 ± 0.26

0.68 ± 0.96 a, b

0.52 ± 0.86a, b, c

SBP (mmHg)

113.32 ± 11.26

113.32 ± 12.22

114.36 ± 10.43a

115.08 ± 11.27a

DBP (mmHg)

73.81 ± 8.89

73.78 ± 8.76

76.27 ± 9.08a, b

75.38 ± 9.06a

Ovarian volume (ml)

7.80 ± 2.86

7.71 ± 2.99

10.15 ± 3.99a, b

10.15 ± 4.32a, b

Hormonal levels

E2 (pmol/L)

324.35 ± 341.91

349.79 ± 366.62

283.87 ± 285.58

284.41 ± 244.71

TT (nmol/L)

1.55 ± 0.53

1.52 ± 0.56

2.41 ± 0.77a, b

2.43 ± 0.77a, b

LH (IU/L)

8.80 ± 11.33

8.61 ± 11.40

13.65 ± 9.01a, b

14.33 ± 13.68a, b

FSH (IU/L)

6.64 ± 3.02

6.71 ± 2.92

5.94 ± 1.89a, b

6.08 ± 2.74a, b

LH/FSH

1.32 ± 1.26

1.28 ± 1.41

2.32 ± 1.20a, b

2.42 ± 1.36a, b

Metabolic profile

Fasting Ins (pmol/L)

65.53 ± 34.31

69.27 ± 40.51

105.28 ± 75.66a, b

107.54 ± 71.75a, b

Fasting Glu (mmol/L)

5.27 ± 0.44

5.35 ± 1.06

5.39 ± 0.84a

5.35 ± 0.62

HOMA-IR

2.24 ± 1.27

2.51 ± 2.64

3.80 ± 3.40a, b

3.77 ± 2.79a, b

TG (mmol/L)

1.03 ± 1.00

1.05 ± 0.68

1.41 ± 1.47a, b

1.45 ± 1.13a, b

TC (mmol/L)

4.30 ± 0.68

4.15 ± 0.72a

4.41 ± 0.81a, b

4.39 ± 0.82b

HDL-C (mmol/L)

1.52 ± 0.32

1.49 ± 0.31

1.39 ± 0.34a, b

1.37 ± 0.35a, b

LDL-C (mmol/L)

2.41 ± 0.57

2.26 ± 0.66a

2.57 ± 0.76a, b

2.51 ± 0.77a, b

non-HDL-C (mmol/L)

2.78 ± 0.60

2.66 ± 0.70

3.03 ± 0.82a, b

3.02 ± 0.80a, b

AI

1.92 ± 0.65

1.88 ± 0.73

2.37 ± 1.03a, b

2.37 ± 1.00a, b

ApoA1 (g/L)

1.46 ± 0.22

1.44 ± 0.19

1.42 ± 0.21a

1.41 ± 0.22a, b

ApoB (g/L)

0.76 ± 0.15

0.73 ± 0.18

0.83 ± 0.21a, b

0.81 ± 0.20a, b

ApoB/apoA1

0.53 ± 0.13

0.52 ± 0.17

0.60 ± 0.18a, b

0.59 ± 0.18a, b

PAF-AH activityd

Plasma PAF-AH (nmol/min/ml)

49.20 ± 10.27

47.20 ± 11.50

48.01 ± 12.50

46.39 ± 13.71

H-PAF-AH (nmol/min/ml)

5.12 ± 1.46

5.17 ± 1.59

4.61 ± 1.98a, b

4.76 ± 1.80

ApoB-PAF-AH (nmol/min/ml)

44.08 ± 9.40

42.03 ± 10.67

43.39 ± 11.49

41.63 ± 12.56

ApoB-PAF-AH/H-PAF-AH

9.07 ± 2.59

8.55 ± 2.29

10.42 ± 4.37a, b

9.33 ± 2.69c

  1. Values are presented as the mean ± SD
  2. Comparisons of all parameters were corrected for differences in age and BMI between the two subgroups except the parameters of age and BMI
  3. a P < 0.05, compared with AA genotype subgroup in controls
  4. bP < 0.05, compared with H1H2 + H2H2 genotype subgroup in controls
  5. cP < 0.05, compared with AA genotype subgroup in PCOS patients
  6. dControls: H1H1 (n = 165), H1H2 + H2H2 (n = 97 + 15); PCOS: H1H1 (n = 182), H1H2 + H2H2 (n = 86 + 13)